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MACROPHAGE migration  inhibitory  factor  (MIF)  has
recently  been  forwarded  as  a  critical  regulator  of
inflammatory conditions,  and  it  has been hypothe-
sized that MIF may have a role in the pathogenesis of
asthma  and  chronic  obstructive  pulmonary  disease
(COPD). Hence, we examined effects of MIF immuno-
neutralization  on  the  development  of  allergen-
induced  eosinophilic  inflammation  as  well  as  on
lipopolysaccaride (LPS)-induced neutrophilic inflam-
mation  in  lungs  of  mice.  Anti-MIF  serum  validated
with respect to MIF neutralizing capacity or normal
rabbit serum (NRS) was administered i.p. repeatedly
during  allergen  aerosol  exposure  of  ovalbumin
(OVA)-immunized  mice  in  an  established  model  of
allergic  asthma,  or  once  before  instillation  of  a
minimal  dose  of  LPS  into  the  airways  of  mice,  a
tentative model of COPD. Anti-MIF treatment did not
affect  the  induced  lung  tissue  eosinophilia  or  the
cellular composition of bronchoalveolar lavage fluid
(BALF)  in  the  asthma  model.  Likewise,  anti-MIF
treatment did not affect the LPS-induced neutrophilia
in lung tissue, BALF, or blood, nor did it reduce BALF
levels of tumor necrosis factor-a (TNF-a ) and macro-
phage inflammatory protein–1a (MIP–1a ). The pres-
ent data suggest that MIF is not critically important
for  allergen-induced  eosinophilic,  and  LPS-induced
neutrophilic responses in lungs of mice. These find-
ings do not support a role of MIF inhibition in the
treatment of inflammatory respiratory diseases.
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Introduction
Macrophage  migration  inhibitory  factor  (MIF)  is
considered  to  be  a  critical  regulator  of  various
inflammatory  conditions.  For  example,  MIF  is  a
pivotal mediator in  the  host response to endotoxic
shock,1 and plays an important role in the develop-
ment  of  the  delayed  type  hypersensitivity  reaction
and  collagen-induced  arthritis  in  mice.2,3 MIF  may
further have a proinflammatory role in the develop-
ment of human acute respiratory distress syndrome.4
MIF was described originally to be a T-cell product,
which  inhibited  the  random  migration  of  macro-
phages.5,6 Interestingly, recent data indicate that MIF
is predominantly expressed by Th2-like T-cells.7 How-
ever, MIF also exists preformed in monocytes/macro-
phages,  eosinophils,  B-cells,  airway  epithelial  cells,
and corticotrophic cells within the anterior pituitary
gland, and is released in  response to various proin-
flammatory stimuli.1,8 –12 MIF shares with other cyto-
kines sensitivity to inhibition by therapeutic concen-
trations  of  glucocorticoids.  However,  at  low
physiological  glucocorticoid  concentrations  MIF
expression is induced.13,14 MIF has the property of
counteracting  anti-inflammatory  and  immunosup-
pressive actions of glucocorticoids.13,14 Anti-MIF ther-
apeutic strategies are thus under development with
the aim to increase the immunosuppressive and anti-
inflammatory  properties  of  endogenously  released
glucocorticoids,  thereby  reducing  the  requirement
for  steroid  therapy  in  a  variety  of  inflammatory
conditions. It has further been suggested that drugs
inhibiting MIF would be effective also in  inflamma-
tory conditions that exhibit steroid resistance.14
Airway mucosal inflammation in allergic asthma is
characterized  by  infiltration  and/or  activation  of
eosinophils,  macrophages, T-lymphocytes,  and  mast
cells.15 Since all these immune cells can produce MIF
in significant quantities, and since elevated levels of
MIF  have  been  detected  in  BALF  from  asthmatic
patients  compared  with  controls,  it  has  been  for-
warded  that  MIF  may  have  a  role  in  eosinophilic
airway disease.9
Recent  studies  have  shown  that  genetically  MIF-
deficient mice are resistant to the lethal effects of a
high  systemic  dose  of  LPS,  but  susceptible  to  a
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D-galactosamine.16 These mice exhibit no impairment
of neutrophil migration to the peritoneum elicited by
thioglycollate; despite diminished neutrophil accumu-
lation in BALF they clear Pseudomonas aeruginosa
instilled into the trachea better than wild type mice.16
Makita  et al.11 recently demonstrated that immuno-
neutralization  of  MIF  attenuates  pulmonary  neu-
trophil  influx  and  acute  lung  injury  induced  by
intraperitoneal  (i.p.)  administration  of  LPS  in  rats.
These  effects  were  associated  with  reduced  BALF
levels  of  macrophage  inflammatory  protein–2,  a
powerful  neutrophil  chemokine.11 Moreover,  it  has
been  demonstrated  that  MIF induces  alveolar  cells/
macrophages  to  secrete  TNF-a and  IL–8,4,17 two
cytokines widely  thought  to  be  critically  important
for neutrophil infiltration in pulmonary inflammatory
conditions  such  as  chronic  obstructive  pulmonary
disease (COPD).18,19
In an attempt to further explore the hypothesis that
MIF  may have  a  role  in  bronchopulmonary  eosino-
philic and neutrophilic inflammation, we examined
effects  of  MIF  inhibition  both  in  an  established
murine  model  of  allergic  asthma,  and  in  a  model
involving  LPS-induced  neutrophilic  inflammation  in
the  lungs  of  mice.  Specifically,  anti-MIF  serum was
administered repeatedly during allergen aerosol expo-
sure  of  immunized  mice,  or  given  once  before




Male C57BL/6 mice (n=184, 6–8 weeks of age), were
purchased  from  Bomholtgaard,  Denmark.  All  mice
were kept in well-controlled animal housing facilities
and had free access to tap water and pelleted food
throughout the experimental period. All animals were
used under protocols approved by the Ethics Commit-
tee  of  the  Faculty  of  Medicine  at  the  University  of
Lund.
Induction of allergic eosinophil-rich airway
inflammation
We have used a protocol slightly modified from that
developed by Brusselle and colleagues.20 On the first
day of the experiment (Day 0), all mice were actively
immunized  by  i.p.  injection  of  10 m g  chicken  OVA
(Grade III, Sigma, St Louis, MO, USA), adsorbed to 1 mg
of alum adjuvant. Starting 14–16 days after immuniza-
tion the mice were exposed once daily during 7 days to
aerosolized saline (SAL) or OVA over a 30-min period
by placing groups of 5–10 awake mice in an exposition
chamber. The aerosol was generated into the chamber
using a nebulizer (Bird 500 ml Inline Micronebulizer
driven  at  4  bar,  Bird  Co.,  Palm  Springs,  CA). The
concentration of OVA in the nebulizer was 1% w /v.
Animals were sacrificed by i.p injection of pentobarbi-
tal 8 h after the last aerosol exposure.
Induction of neutrophil-rich airway inflammation
Groups of mice received one intratracheal instillation
of a low dose of Escherichia coli LPS (Difco Lab., MI,
USA, 4 m g/kg, i.e. , 0.08 m g/animal, diluted in , 20 m l
saline) or SAL. The present LPS dose is comparable
with occupational levels.21 For example, it has been
estimated  that  cotton  mill  workers  are  exposed  to
60 m g  endotoxin  per  day.22 In  preliminary  dose–
response experiments our selected dose of LPS was
shown  to  induce  submaximal  responses  regarding
TNF-a levels and total cell numbers in BALF. For the
instillation  procedure,  animals  were  anaesthetized
with enflurane, and a blunted cannula was introduced
perorally into the trachea. Animals were sacrificed by
i.p injection of pentobarbital 4 or 24 h after LPS or SAL
administration.
In vivoneutralization of MIF
Starting  the  day  before  the  first  allergen  aerosol
challenge, mice (n = 20) were injected i.p. with 200 m l
of rabbit anti-murine MIF serum; this treatment was
then repeated every 3 days until termination of the
experiment. Control mice (n = 20) were injected with
a  similar  volume  (200 m l)  of  NRS.  Other  groups
received no treatment at all. Groups of mice subjected
to  intratracheal  LPS  instillation  received  one  i.p.
injection of anti-MIF serum (200 m l), NRS, or SAL 12 h
before LPS challenge (n = 8 in each group). This anti-
MIF treatment has previously been shown to neutralize
MIF in vivo using the same dose level and administra-
tion route in mice as in this study.1,23 Components in
serum  may  have  some  capacity  to  downregulate
inflammatory  responses,  underscoring  the need  for
proper  control  groups  in  the  evaluation  of  experi-
ments using anti-serum. Thus, in this study groups of
mice treated with anti-MIF serum were compared with
corresponding groups of mice treated with NRS.
In  additional  experiments  we  explored  whether
anti-MIF  treatment  might  be  effective  via  the  local
route. Groups of mice (n = 4 in each group) received
15 m l  anti-MIF  serum  or  NRS  administered  intra-
tracheally,  alone  or  together  with  LPS  solution
(4 m g/kg) in a total volume of , 20 m l.
The present batch of anti-MIF serum was checked
for  bioactivity  at  our  laboratory  using  a  protocol,
which has previously been employed to analyse the
role of MIF in endotoxaemia.16 Groups of mice (n =
5–6  in  each  group)  received  one  i.p.  injection  of
anti-MIF serum (200 m l), NRS, or SAL 2 h before i.p.
injection with a high dose of LPS (25mg/kg). Ninety
minutes after LPS challenge blood was collected by
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indicator  of  LPS-induced  plasma  extravasation,  the
haematocrit  was  determined  by  an  automated
haematology analyser (Sysmex K–4500, TOA Medical
Electronics Co., Kobe, Japan).
Histological analysis of allergic airway
inflammation
Lung tissue specimens obtained 8 h after the last OVA
or SAL exposure were immersed overnight in Stefani-
ni’s fixative (2% paraformaldehyde and 0.2% picric acid
in 0.1M phosphate buffer, pH 7.2), rinsed repeatedly
in  buffer  (Tyrode’s  buffer  supplemented  with  10%
sucrose),  frozen  in  mounting  medium  (Tissue-Tek,
Miles Inc, Elkhart, IN, USA), and stored at –80°C until
sectioning. Eosinophils were detected by histochem-
ical visualization of cyanide-resistant eosinophil perox-
idase (EPO) activity.24–26 Briefly, cryosections (10 m m)
were incubated for 8 min at room temperature in PBS
buffer (pH 7.4) supplemented with 3,3-diaminobenzi-
dine tetrahydrochloride (60 mg/100ml, Sigma), 30%
H2O2 (0.3 ml/100 ml),  and  NaCN  (120 mg/100ml).
Slides  were  then  rinsed  in  water  and  mounted  in
Kaiser’s medium (Merck, Darmstadt, Germany). Eosi-
nophils were identified by their dark-brown reaction
product. For evaluation of the number of eosinophils
in  pulmonary  tissue,  40  randomly  selected  areas
(0.04 mm2 each) in one lung section from each animal
were examined. The number of eosinophils in the 40
areas was counted at a magnification of 400, and the
mean  was  expressed  as  eosinophils/unit  area.  Cell
counts were made in a blinded fashion. For assessment
of general airway morphology sections were stained
with haematoxylin and erythrosin. Lung tissue speci-
mens and tracheobronchial lymph nodes immersed in
buffered 4% paraformaldehyde (pH 7.2), dehydrated,
and embedded in paraffin, were used for immunohis-
tochemical visualization of MIF-expressing cells. Sec-
tions  were  incubated  overnight  in  4°C  in  a  moist
chamber  with  a  1:800  dilution  of  the  rabbit  anti-
murine MIF serum. The anti-MIF  serum used in  the
present study has previously been used for immunohis-
tochemistry.1,2 NRS at a dilution of 1:800 or PBS were
used  in  control  sections.  The  site  of  the  antigen-
antibody  reaction  was  revealed  by  application  of
fluorescein isothiocyanate-conjugated swine antisera
directed at rabbit immunoglobulins (DAKO, Glostrup,
Denmark) diluted 1:80 for 1h at room temperature.
Histological analysis of LPS-induced airway
inflammation
Lung tissue specimens obtained 4 h and 24 h after LPS
or  SAL  challenge  were  immersed  in  buffered  4%
paraformaldehyde (pH 7.2), dehydrated, and embed-
ded in paraffin. One section (6 m m) per animal (n = 3
from each group) were stained with haematoxylin and
erythrosin  to  examine  the  extent  of  pulmonary
inflammation. Other sections (one per animal, n = 3
from each group) were used for immunohistochemical
demonstration of neutrophils in lung tissue. Sections
were incubated overnight in 4°C in a moist chamber
with  a  1:200  dilution  of  rabbit  antisera  directed  at
human  myeloperoxidase  (MPO,  DAKO,  Glostrup,
Denmark). The site of the antigen-antibody reaction
was revealed by application of fluorescein isothiocya-
nate-conjugated  swine  antisera  directed  at  rabbit
immunoglobulins (DAKO, Glostrup, Denmark) for 1 h
at room temperature. In control sections, omitting the
primary antibody,  only slight yellowish auto-fluores-
cence was found.
Analysis of cells in peripheral blood and BALF,
and measurement of TNF-a and MIP–1a levels in
BALF and plasma
Animals were anaesthetized with an i.p. injection of
pentobarbital. The  chest  was  opened  and  a  blood
sample  was  collected  via  the  still  beating  heart. A
tracheal  cannula  was  inserted  via  a  midcervical
incision. The  airways  were  lavaged  once  (LPS-chal-
lenged mice) or twice (OVA-exposed mice) with 0.7 ml
of PBS (Life Technologies, Paisley, UK). The BALF was
immediately centrifuged (10min, 4°C, 160 ´ g ). Cell
pellets were resuspended in 250 m l PBS for total and
differential cell counting and the supernatants were
rapidly frozen. Differential counting was performed on
May-Gr¨ unwald-Giemsa  stained  cytospins  and  blood
smears. Between 200 and 500 cells were counted on
each cytospin, and 100 cells were counted on each
blood smear. Commercial ELISA  kits (R&D  systems,
MN, USA) were used to measure levels of TNF-a and
MIP–1a in the BALF of LPS and SAL challenged mice.
TNF-a levels were also measured in plasma obtained
from LPS challenged mice. The limit of detection was
5.1 pg/ml for TNF-a , and 1.5 pg/ml for MIP–1a .
Statistics
Data  are  expressed  as  mean  ±  SEM.  To  calculate
significance  levels  between  treatment  groups,  the
Student’s t-test was used throughout the study. ELISA
values below detection limits were assigned the value
of the detection limit. Probabilities <0.05 were used as
the generally accepted level of statistical significance
for differences between mean values.
Results
Additional validation of the present anti-MIF
sera
Exposure of a high dose of endotoxin  is known to
cause  plasma  extravasation  and  subsequent  loss  of
circulating plasma volume.27,28 In order to ascertain a
MIF independent pulmonary inflammation in mice
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crit was determined 90 min after i.p. LPS challenge as
a measure of plasma extravasation. The haematocrit
was  significantly  increased  in  LPS-challenged  mice
compared with SAL-challenged mice (53.1 ± 4.0% vs.
45.2 ± 6.2%, P<0.001). This response was inhibited in
mice  treated  with  anti-MIF  serum  before  LPS  chal-
lenge (45.7 ± 2.1% vs.50.8 ± 5.0% in corresponding
NRS-treated mice, P<0.01).
Effect of anti-MIF treatment on
allergen-induced airway inflammation
To assess the role of MIF in allergic airway inflamma-
tion, lung tissue eosinophilia and cellular composition
of BALF were determined in anti-MIF-treated and NRS-
treated mice 8 h after last allergen aerosol exposure.
The number of eosinophils in lung tissue was similar
in allergen aerosol exposed anti-MIF-treated and NRS-
treated mice (Fig. 1). Likewise, total cellular content
(data not shown) and the percentage of eosinophils,
neutrophils, lymphocytes, and macrophages in BALF
did  not  differ  significantly  between  anti-MIF-treated
and NRS-treated mice after allergen aerosol exposure
(Fig. 2).
Untreated  SAL  and  OVA  exposed  mice  were  also
included  in  the  study,  to  check  that  the  present
inflammation was specifically induced by OVA chal-
lenge. Histologic  analysis  of  lungs  taken  from OVA-
exposed mice revealed the presence of peribronchial
and perivascular infiltrates, whereas lung tissue taken
from SAL-exposed animals showed normal lung histol-
ogy.  Allergen  aerosol  exposures  caused  a  marked
eosinophilia in pulmonary tissue (12.1 ± 2.0 vs. 3.0 ±
0.5  eosinophils/unit  area  in  SAL  exposed  mice,
P<0.01). A significant increase in  the percentage of
eosinophils  (44.4  ±  12.2%  vs.  2.2  ±  1.6%  in  SAL-
exposed mice, P<0.05), neutrophils (1.7 ± 0.5% vs.
0.1  ±  0.1%  in  SAL-exposed  mice,  P<0.05),  and
lymphocytes  (7.5  ±  1.6%  vs.  0.8  ±  0.3%  in  SAL-
exposed mice, P<0.01) was demonstrated in response
to OVA challenge.
Immunohistochemistry  was  used  to  visualize  the
MIF-expressing cells in the pulmonary infiltrates and
tracheobronchial  lymph  nodes  of  OVA-challenged
mice. A majority of the leukocytes in the perivascular
and  peribronchial  pulmonary  infiltrates  were  MIF-
positive (Fig. 3a). Interestingly, large, intensely MIF-
positive cells with dendritic shape were seen in the
superficial  cortex  of  the  tracheobronchial  lymph
nodes  in  OVA-challenged  mice  (Fig.  3b).  Lympho-
cytes, mainly located in the cortex, were also stained
for MIF, although less intensely (Fig. 3c). The exact
identity  of  the  MIF-positive  cells  was  not  further
evaluated in the present study. No staining except for
a yellowish auto-fluorescence (compare Fig. 3a and d)
was observed in control sections where NRS or PBS
was  used  instead  of  the  anti-MIF  serum  (not
shown).
Characterization of the present ‘low dose’ LPS
model
Intratracheal instillation of a minimal dose of LPS into
the  lower  airways  of  mice  induced  a  significant
increase  in  total  cellular  content  of  BALF  4 h  after
challenge  (51.9  ±  5.5  vs.  10.6  ±  2.6  BALF  cells  ´
104/ml  in  SAL  challenged  controls,  P<0.001). This
increase remained 24h after LPS instillation (33.8 ±
4.6  vs.  12.6  ±  1.8  BALF  cells  ´ 104/ml  in  SAL
challenged  controls,  P<0.01).  The  percentage  of
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FIG. 1. Effect of anti-MIF treatment on allergen-induced lung
tissue  eosinophilia. Mice  were  immunized  and  then  chal-
lenged  daily  with  aerosolized  OVA.  Data  are  from  two
independent experiments and are presented as mean ± SEM.
NRS = NRS-treated mice (n=20), anti-MIF = anti-MIF-treated
mice  (n=20).  Lung  tissue  eosinophilia  did  not  differ  sig-
nificantly between anti-MIF-treated and NRS-treated mice.
FIG.  2.  Cellular  composition  of  BALF  in  immunized  and
allergen  challenged  mice  treated  with  anti-MIF  serum  or
NRS. Data are presented as mean ± SEM. NRS = NRS-treated
mice (n=10), anti-MIF = anti-MIF-treated mice (n=10). Eos. =
eosinophils, Neutro. = neutrophils, Lymph. = lymphocytes,
Macro.  =  macrophages.  OVA  challenge  induced  similar
changes of the cellular profile in BALF of  anti-MIF-treated
and NRS-treated mice.MIF independent pulmonary inflammation in mice
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FIG. 3. Immunohistochemistry. Visualization of  MIF-expressing cells  in the pulmonary infiltrates (a) and tracheobronchial
lymph nodes (b and c) of OVA challenged mice, and visualization of MPO-positive cells in the lungs of LPS-challenged mice (d).
A majority of the leukocytes in the pulmonary infiltrates (arrows) of OVA-challenged mice were stained with anti-MIF serum (a).
Interestingly, large,  intensely  MIF-positive cells  with  dendritic  shape  (arrow)  were  seen  in  the  superficial  cortex  of  the
tracheobronchial lymph nodes in OVA-challenged mice (b). Lymphocytes, mainly located in the cortex, were also stained for
MIF, although less intensely (c). In deeper portions of the lymph nodes many cells were unstained (c). A multifocal perivascular
and peribronchial MPO-positive (neutrophilic) distribution (arrows) was seen at 4h after intratracheal LPS-challenge (d). In (a)
and (d) a slight yellowish auto-fluorescence, mainly located in the lung parenchyma, is observed. B = bronchus, V = blood
vessel. Original magnification 3 250.neutrophils in BALF was strikingly increased at both
4 h and 24 h after LPS challenge (77.3 ± 2.7% and 53.1
± 5.9%, respectively, vs. 6.8 ± 4.3% and 8.3 ± 5.9%,
respectively,  in  SAL-challenged  controls,  P<0.001).
The  percentage  of  lymphocytes  remained  low  4 h
after LPS challenge (0.8 ± 0.2% vs. 1.4 ± 0.3% in SAL-
challenged  controls).  However,  an  increase  of  lym-
phocytes was observed 24 h after LPS instillation (2.3
±  0.5%  vs.  0.9  ±  0.3%  in  SAL-challenged  controls,
P<0.05).
The percentage of polymorphonuclear leukocytes
(PMN)  in  peripheral  blood  increased  rapidly  after
intratracheal LPS instillation (48.8 ± 3.1% vs. 21.2 ±
3.1% in SAL-challenged controls at the 4 h time point,
P<0.001). At 24 h after LPS instillation the percentage
of PMN in peripheral blood had returned to baseline
levels (23.1 ± 1.6% vs. 20.1 ± 3.5% in SAL-challenged
controls).
Histological  analysis  of  lungs  taken  4  hours  after
LPS challenge demonstrated a moderate neutrophilia
perivascularly  and  peribronchially  (Fig.  3d).  Neu-
trophils  were  also  detected  in  alveolar  walls  and
spaces. A  similar,  but  reduced,  distribution  of  neu-
trophils was observed 24 hours post LPS instillation
(not shown).
High  levels  of TNF-a were  detected  in  BALF  4 h
after LPS challenge (3302.7 ± 437.9 pg/ml versus 17.0
± 7.0 pg/ml in SAL-challenged controls, P<0.001). A
small  increase  in  levels  of  TNF-a could  still  be
detected 24 h after LPS challenge (16.3 ± 3.1 pg/ml vs.
5.3 ± 0.2 pg/ml in SAL-challenged controls, P<0.01).
Intratracheal  instillation  of  LPS  also  induced  a  sig-
nificant increase of MIP–1a levels in BALF 4 h after
challenge (3942.6 ± 280.4 pg/ml vs. 26.2 ± 14.9 pg/ml
in SAL-challenged controls, P<0.001).
Effect of anti-MIF treatment on LPS-induced
airway inflammation
To  examine  the  role  of  MIF  in  LPS-induced  airway
inflammation,  cellular  profile  in  BALF,  and  neu-
trophilia in lung tissue and blood were determined in
anti-MIF-treated and NRS-treated mice. At 4 h and 24 h
after intratracheal instillation of a low dose LPS total
cellular content (data not shown) and the percentage
of  neutrophils,  lymphocytes,  and  macrophages  in
BALF were similar in LPS-challenged anti-MIF-treated
and NRS-treated mice (Fig. 4a and b). Consistent with
the findings in BALF , the number of PMN in blood did
not differ significantly between anti-MIF-treated and
NRS-treated animals at either time points (Fig. 4a and
b). Also,  no  obvious  difference  in  lung  tissue  neu-
trophilia was observed between anti-MIF–treated and
NRS-treated animals at 4 h and 24h after LPS challenge
(data not shown).
Since  MIF  has  been  reported  to  modulate  the
expression  of TNF-a and  chemokines  in  models  of
endotoxaemia and acute lung injury,11,16 TNF-a and
MIP–1a levels were measured in LPS-challenged anti-
MIF-treated  and  NRS-treated  mice. At  4 h  after  LPS
instillation mice treated with anti-MIF serum exhib-
ited similarly increased levels of TNF-a and MIP–1a in
BALF as NRS-treated mice (Fig. 5). Equally low levels
of TNF-a in BALF  were observed in anti-MIF-treated
and NRS-treated mice at 24 h after LPS challenge (12.5
±  2.6pg/ml  and  15.9  ±  4.8 pg/ml,  respectively).
Plasma levels of TNF-a were below detection limit in
both anti-MIF-treated and NRS-treated mice at 4 h after
LPS challenge (data not shown).
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FIG. 4. Cellular composition of BALF and percentage of PMN
in blood of anti-MIF-treated and NRS-treated mice 4h (a) and
24h (b) after LPS challenge. Data are presented as mean ±
SEM. NRS  = NRS-treated mice  (n=8), anti-MIF = anti-MIF-
treated mice (n=8). Eos. = eosinophils, Neutro. = neutrophils,
Lymph. = lymphocytes, Macro. = macrophages. At both 4h
(a)  and  24h  (b)  after  LPS  challenge,  a  similar  cellular
composition of BALF was demonstrated in anti-MIF-treated
and NRS-treated mice. Consistent with the findings in BALF,
the  number  of  PMN  in  blood  did  not  differ  significantly
between anti-MIF-treated and  NRS-treated  animals  4h  (a)
and  24h  (b)  after  LPS  challenge.  (Epithelial  cells  and
eosinophils in BALF are not included in the figures.)Effect of intratracheal anti-MIF treatment on
LPS-induced airway inflammation
LPS-challenged mice treated with topical intratracheal
anti-MIF  serum  or  NRS  exhibited  a  similar  neu-
trophilia in BALF at the 4-h time point (86.5 ± 1.4%
and  82.4  ± 2.0%  neutrophils  in  BALF ,  respectively).
Also 24 h after LPS challenge no significant difference
in  BALF  neutrophilia  was  observed  between  the
intratracheally treated mice. Anti-MIF-treated and NRS-
treated mice exhibited 68.0 ± 1.6% and 71.0 ± 4.8%
neutrophils  in  BALF,  respectively.  The  BALF  neu-
trophilia in mice receiving intratracheal doses of anti-
MIF serum or NRS together with LPS was somewhat
increased  when  compared  with  that  observed  in
BALF  from animals receiving LPS  challenge only. In
accord,  SAL-challenged  mice  treated  intratracheally
with NRS demonstrated a mild neutrophilia  at  both
the 4- and 24-h time points (35.9 ± 13.0 and 39.4 ±
11.8 % neutrophils in BALF, respectively).
Discussion
This study demonstrates that anti-MIF treatment does
not  have  any  major  effects  on  the  eosinophil-rich
airway inflammation occurring in a murine model of
allergic asthma. Similarly, anti-MIF treatment did not
change the neutrophilic inflammatory response seen
after instillation of a low dose of LPS into the lower
airways  of  mice. Although  we  cannot  exclude  the
possibility  that  MIF  may  regulate  other  indices  of
pulmonary inflammation than measured in this study,
the present data do not support the view that MIF is
critically involved in pulmonary eosinophilic or neu-
trophilic inflammatory conditions.
Human  asthma  is  characterized  by  peribronchial
inflammatory infiltrates, mainly consisting of eosino-
phils,  T-lymphocytes,  and  macrophages.15,29 Given
that all these immune cells express MIF in significant
quantities, and that MIF has proinflammatory effects,
MIF has been implicated in development of asthma
and  other  inflammatory  airway  diseases.9,14 Moreo-
ver,  IL–5,  a  cytokine  considered  pivotal  for  the
recruitment  of  eosinophils  to  the  airways  in  both
human asthma and allergic mice, induces MIF secre-
tion  by  cultured  eosinophils.9 Indeed,  abnormally
high levels of MIF have been detected in BALF from
asthmatic  subjects.9 In  similarity  to  human asthma,
the  present  allergic  mice  exhibit  peribronchial  and
perivascular infiltrates of eosinophils, T-lymphocytes,
and macrophages.25,26 The present study also showed
the presence of MIF-positive cells in the pulmonary
infiltrates.  In  addition,  an  intriguing  distribution  of
MIF-positive cells was observed in  the tracheobron-
chial  lymph  nodes  of  the  allergic  mice,  a  location
where essential  immune responses to antigens take
place. Hence, this allergic model would be well suited
for exploration of anti-inflammatory efficacy of anti-
MIF active compounds.
It was hypothesized that anti-MIF treatment might
inhibit  the allergic responses in the present  asthma
model both by the enhancement of anti-inflammatory
effects  of  endogenous  corticosteroids  no  longer
counter-regulated by MIF, and by diminished produc-
tion  of  MIF-inducible  proinflammatory  cytokines.
However,  immunoneutralization  of  MIF  during  the
period of allergen aerosol challenge did not influence
the magnitude of pulmonary eosinophilia and cellular
composition of inflammatory cells obtained by BAL.
Hence, the present study failed to support the view
that MIF is a critical regulator of pulmonary eosino-
philic inflammation.
Instillation of a low dose of LPS into the airways of
mice  proved  sufficient  for  producing  consistent,
predominantly neutrophilic pulmonary inflammation
with  moderate  neutrophilia  perivascularly  and  peri-
bronchially,  but  also  involving  alveolar  walls  and
spaces. These features are reminiscent of the pathol-
ogy  of  COPD.29 In  addition,  chronic  exposure  to
endotoxin,  as  a  component  of  organic  dust  in
occupational  settings,  has  been  related  to  develop-
ment  of  COPD-like  conditions.30–32 The  potential
relevance of the present model to human COPD may
further  be  supported  by  studies  suggesting  that
inhaled LPS, as a constituent of cigarette smoke, is of
importance  for  the  development  of  COPD.33 The
present  demonstration  of  LPS-induced  increases  in
BALF TNF-a and MIP–1a levels is also of interest in
relation  to  COPD,  since  these  two  mediators  are
potentially  important  for  pulmonary  neutrophil
recruitment.18,34,35 These  findings  together  with  an
increase in  the percentage of lymphocytes in  BALF
and lack of eosinophilia, support the possibility that
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FIG. 5. Levels of TNF-a and MIP–1a in BALF 4h after LPS
instillation of mice treated with anti-MIF serum or NRS. Data
are presented as mean ± SEM. NRS = NRS-treated animals
(n=8), anti-MIF = anti-MIF-treated animals (n=8). Mice treated
with anti-MIF serum exhibited similar levels of TNF-a and
MIP–1a in BALF as NRS-treated mice.the  present  LPS  challenge  produced  a  potentially
useful model of COPD.29
In  contrast  to  most  cytokines,  MIF  mRNA  and
protein are expressed constitutively in a variety of cell
types, such as monocytes/macrophages, T-cells, airway
epithelial cells, and pituitary endocrine cells. Proin-
flammatory  stimuli,  including  LPS,  are  known  to
increase MIF mRNA expression above the level present
constitutively.8,12 LPS administrated systemically (i.p.)
in  high  doses  has  been  used  in  earlier  studies  to
elucidate the role of MIF in endotoxaemia and acute
lung injury.1,11,12,16 For example, treatment of mice
with anti-MIF serum conferred full protection to the
lethal effects of LPS (17.5 mg/kg) administrated i.p.1
Consistent with these previous findings and confirm-
ing the validation of the employed anti-MIF serum, the
present study showed that anti-MIF treatment inhibits
plasma extravasation in response to a high systemic
dose of LPS.
In a rat model of acute lung injury, Makita et al.11
demonstrated  that  anti-MIF  treatment  reduced  the
number  of  neutrophils  per  alveolus  and  the  BALF
neutrophilia,  induced  by  a  high  dose  of  LPS  given
systemically.  In  mice,  i.p.  administration  of  LPS
(1–20 mg/kg) does not induce  transpulmonary neu-
trophil migration and infiltration of neutrophils into
the alveolar space, but only neutrophil sequestration
within  the  lung  vasculature.36 –38 In  this  study,  a
fraction of the previously employed i.p. doses of LPS
(250–5000-fold less) was given locally into the airways.
Reflecting the low dose and route of administration,
plasma levels of TNF-a were below detection limit at
4 h after LPS challenge. In  apparent  contrast to the
important  role  of  MIF  in  host  responses  to  high
systemic  doses  of  LPS,  anti-MIF  treatment  did  not
change  the  neutrophil-rich  inflammatory  response
induced  by  this  mode  of  LPS  exposure. To  explain
these data it is suggested that the importance of MIF in
different  models of LPS-induced host reactions may
vary depending on the dose and/or the administration
route of LPS. In accord, it has previously been shown
that the mechanisms behind host responses to LPS may
be completely different in models using high or low
doses of LPS.39 Genetically MIF-deficient mice are also
resistant to the lethal effects of a high systemic dose of
LPS, but susceptible to a combination of a low dose of
LPS  and  D-galactosamine.16 The  demonstration  that
MIF  is  not  involved  in  the  present  pulmonary
neutrophilic inflammation may reduce the promise of
anti-MIF compounds as future COPD drugs.
In conclusion, the present data suggest that MIF is
not  critically important  for  allergic  eosinophilic,  or
LPS-induced neutrophilic inflammation, in airways of
mice. If translatable to human disease conditions,40
these  findings  do  not  support  the  notion  that  MIF
inhibitors  will  be  effective  against  eosinophilic  or
neutrophilic  respiratory  diseases,  such  as  allergic
asthma and COPD.
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